Citadel Advisors
APRE icon

Citadel Advisors’s Aprea Therapeutics APRE Stock Holding History

Citadel Advisors’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,115
Closed -$104K – 14667
2022
Q4 		$104K Sell
16,115
-490
-3% -$5.17K ﹤0.01% 11168
2022
Q3 		$216K Sell
16,605
-1,690
-9% -$30K ﹤0.01% 10256
2022
Q2 		$271K Sell
18,295
-65
-0.4% -$1.5K ﹤0.01% 10030
2022
Q1 		$683K Buy
18,360
+13,750
+298% +$564K ﹤0.01% 8631
2021
Q4 		$265K Buy
4,610
+2,225
+93% +$197K ﹤0.01% 11195
2021
Q3 		$244K Buy
2,385
+1,310
+122% +$119K ﹤0.01% 11526
2021
Q2 		$105K Buy
1,075
+205
+24% +$18.9K ﹤0.01% 12875
2021
Q1 		$89K Buy
+870
New +$101K ﹤0.01% 12565

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's APRE Position: Q1 2026 in Review

Citadel Advisors sold out of Aprea Therapeutics (APRE) in Q1 2026, closing a stake of 51,041 shares — an estimated $43.5K sold.

Citadel Advisors first reported a position in APRE in Q4 2019 and held it in 12 quarters. The position peaked at $14.2M in Q4 2019. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

  • Citadel Advisors reported no remaining Aprea Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 51,041 Aprea Therapeutics shares in Q1 2026, an estimated $43.5K.
  • Citadel Advisors first reported a position in Aprea Therapeutics in Q4 2019 and held it in 12 quarters.
  • Citadel Advisors's Aprea Therapeutics position peaked at $14.2M in Q4 2019.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.